Literature DB >> 20979736

[An investigation of signal transduction pathway of colonic mucosal toll-like receptor 4 in patients with diarrhea-irritable bowel syndrome].

Xue-mei Wang1, Yu-lan Liu.   

Abstract

OBJECTIVE: To study the expressions of TLR4, CD14, MD-2 and NF-κB in colonic mucosa in patients with diarrhea-irritable bowel syndrome (IBS-D), and compared with normal subjects. The purpose of this study is to explore the role of TLR4 and TLR4 signal transduction pathway in the pathogenesis of IBS-D.
METHODS: The expressions of TLR4, CD14, MD-2 and NF-κB in colon mucosa were examined by immunohistochemistry (IHC) in 30 IBS-D patients and 12 healthy volunteers separately. The average absorbance (A value) of TLR4 was analyzed. The positive expression rates of CD14, MD-2 and NF-κB of colonic mucosa were studied.
RESULTS: Compared with healthy controls, significant upregulation of TLR4 expression relative to controls was found in colon mucosa of IBS-D.A value of TLR4 in IBS-D was significantly higher (0.3971±0.0996 vs 0.3044±0.0481). The positive rate and intensity of NF-κB in IBS-D were significantly higher than those in healthy. The number of positive cells of MD-2 showed significant increase in lamina propria of IBS-D against controls. The percent of CD14 positive was upregulated in lamina propria in IBS-D. The expressions of MD-2 and CD14 in intestine epithelial cell were low or negative.
CONCLUSIONS: There is the activation of the signal transduction pathway of TLR4/NF-κB in the colonic mucosa of patients with IBS-D. Up-regulated expression of TLR4 in IBS patients suppose that it might contribute to occurrence of IBS-D.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20979736

Source DB:  PubMed          Journal:  Zhonghua Nei Ke Za Zhi        ISSN: 0578-1426


  1 in total

1.  Role of High-affinity Choline Transporter 1 in Colonic Hypermotility in a Rat Model of Irritable Bowel Syndrome.

Authors:  Meng-Juan Lin; Bao-Ping Yu
Journal:  J Neurogastroenterol Motil       Date:  2018-10-01       Impact factor: 4.924

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.